AI-aided Analysis Platform for Prediction of Tumor Neoantigen

Creative Biolabs has a top scientific research team who are proficient in bioinformatics and vaccine science. With the continuous advancement of the concept of precision medicine, the development of personalized vaccines against complex cancers has become the focus of scientists' research. Advances in AI technology have brought hope to the implementation of this strategy. And that's what the Creative Biolabs’ team excels at.

According to a survey, the size of the global precision medical market will grow at a rate of 15% per year from 2016 to 2020, and it is estimated that by 2020, the size of the global precision medical market will break 100 billion, reaching 105 billion US dollars. Precision medicine usually includes two aspects of diagnosis and treatment, of which precision is the core and gene sequencing is the basis. From the perspective of application, current genetic testing, cellular immunotherapy, gene editing, tumor-targeted drugs, and personalized tumor vaccines are all segmentation of precision medicine. Creative Biolabs also started to research precision medicine in the early days and took the lead in using genetic sequencing and artificial intelligence to implement personalized immunotherapy for tumors.

Prediction of Tumor Neoantigen Using AI-aided Analysis Platform

Analyze tumor mutations through genetic sequencing, and then predict, design, and prepare neoantigen vaccines against the mutant genes, return the vaccines to patients and stimulate patients’ autoimmunity to kill tumor cells. This is basic strategy of Creative Biolabs' personalized tumor vaccine.

AI-aided Analysis Platform for Prediction of Tumor Neoantigen

NetMHC, MHCflurry, and other machine learning models based on in vitro peptide-HLA binding databases all have good predictive binding power, but have weak predictive ability for actual HLA presentation. To accurately predict which mutations are tumor neoantigens, it is necessary to test all mutant epitopes, which requires a large amount of investment in samples, reagent consumption, and analysis time. Based on AI technology, Creative Biolabs has developed an accurate HLA-I epitope prediction algorithm to optimize the identification of neoantigen and provide key technical support for the development of personalized cancer vaccines. We analyze from various tumors and normal tissues, and study from three aspects. First, conduct HLA immunoprecipitation and mass spectrometry identification, then sequence and classify the DNA of normal tissues and obtain exomes, and finally extract total RNA from them and perform transcriptome sequencing to evaluate gene expression. Train these three databases into a neural network model that can learn allele-peptide mapping and allele-specific presentation together. This neural network algorithm can detect the mutant peptides generated by multiple mutations at the same time. Based on the mutant peptides generated by tumor mutations, the affinity of the above mutant peptides with MHC I and II molecules can be predicted. Combining with the tumor neoantigen database in the population, predicting and screening high-quality tumor neoantigen sequences makes possible.

Features of AI-aided Tumor Neoantigen Prediction

  • Rich database and high-quality algorithms ensure the accuracy of predictions
  • Flexible deep learning capabilities
  • Strong support for the design of individualized vaccines
  • Can cooperate with high-efficient neoantigen in vitro evaluation platform to develop personalized cancer vaccine

With the help of AI technology and rich experience in vaccine development, Creative Biolabs successfully launched a highly accurate tumor neoantigen prediction algorithm, added wings to the development of individualized cancer vaccines, and advanced the development of effective cancer therapies with a big leap.


All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.


Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONTACT US

USA

Tel:
Fax:
Email:
UK

Tel:
Email:
Germany

Tel:
Email:


Follow us on

Shopping Basket